scholarly journals OmicInt package: exploring omics data and regulatory networks using integrative analyses and machine learning

Author(s):  
Auste Kanapeckaite
2021 ◽  
Vol 49 ◽  
pp. 107739
Author(s):  
Parminder S. Reel ◽  
Smarti Reel ◽  
Ewan Pearson ◽  
Emanuele Trucco ◽  
Emily Jefferson

Biomolecules ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 565
Author(s):  
Satoshi Takahashi ◽  
Masamichi Takahashi ◽  
Shota Tanaka ◽  
Shunsaku Takayanagi ◽  
Hirokazu Takami ◽  
...  

Although the incidence of central nervous system (CNS) cancers is not high, it significantly reduces a patient’s quality of life and results in high mortality rates. A low incidence also means a low number of cases, which in turn means a low amount of information. To compensate, researchers have tried to increase the amount of information available from a single test using high-throughput technologies. This approach, referred to as single-omics analysis, has only been partially successful as one type of data may not be able to appropriately describe all the characteristics of a tumor. It is presently unclear what type of data can describe a particular clinical situation. One way to solve this problem is to use multi-omics data. When using many types of data, a selected data type or a combination of them may effectively resolve a clinical question. Hence, we conducted a comprehensive survey of papers in the field of neuro-oncology that used multi-omics data for analysis and found that most of the papers utilized machine learning techniques. This fact shows that it is useful to utilize machine learning techniques in multi-omics analysis. In this review, we discuss the current status of multi-omics analysis in the field of neuro-oncology and the importance of using machine learning techniques.


Author(s):  
Md. Nasfikur Rahman Khan ◽  
Sarmila Yesmin ◽  
Mahbuba Aktar ◽  
Kuraish Bin Quader Chowdhury ◽  
Kashshaf Labeeb ◽  
...  
Keyword(s):  

2018 ◽  
Vol 19 (S14) ◽  
Author(s):  
Diogo Manuel Carvalho Leite ◽  
Xavier Brochet ◽  
Grégory Resch ◽  
Yok-Ai Que ◽  
Aitana Neves ◽  
...  

BMC Genomics ◽  
2015 ◽  
Vol 16 (Suppl 1) ◽  
pp. S2 ◽  
Author(s):  
Anna L Swan ◽  
Dov J Stekel ◽  
Charlie Hodgman ◽  
David Allaway ◽  
Mohammed H Alqahtani ◽  
...  

Nanomaterials ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 2385
Author(s):  
Tae Hwan Shin ◽  
Saraswathy Nithiyanandam ◽  
Da Yeon Lee ◽  
Do Hyeon Kwon ◽  
Ji Su Hwang ◽  
...  

Nanoparticles (NPs) in biomedical applications have benefits owing to their small size. However, their intricate and sensitive nature makes an evaluation of the adverse effects of NPs on health necessary and challenging. Since there are limitations to conventional toxicological methods and omics analyses provide a more comprehensive molecular profiling of multifactorial biological systems, omics approaches are necessary to evaluate nanotoxicity. Compared to a single omics layer, integrated omics across multiple omics layers provides more sensitive and comprehensive details on NP-induced toxicity based on network integration analysis. As multi-omics data are heterogeneous and massive, computational methods such as machine learning (ML) have been applied for investigating correlation among each omics. This integration of omics and ML approaches will be helpful for analyzing nanotoxicity. To that end, mechanobiology has been applied for evaluating the biophysical changes in NPs by measuring the traction force and rigidity sensing in NP-treated cells using a sub-elastomeric pillar. Therefore, integrated omics approaches are suitable for elucidating mechanobiological effects exerted by NPs. These technologies will be valuable for expanding the safety evaluations of NPs. Here, we review the integration of omics, ML, and mechanobiology for evaluating nanotoxicity.


2020 ◽  
Author(s):  
Mufang Ying ◽  
Peter Rehani ◽  
Panagiotis Roussos ◽  
Daifeng Wang

AbstractStrong phenotype-genotype associations have been reported across brain diseases. However, understanding underlying gene regulatory mechanisms remains challenging, especially at the cellular level. To address this, we integrated the multi-omics data at the cellular resolution of the human brain: cell-type chromatin interactions, epigenomics and single cell transcriptomics, and predicted cell-type gene regulatory networks linking transcription factors, distal regulatory elements and target genes (e.g., excitatory and inhibitory neurons, microglia, oligodendrocyte). Using these cell-type networks and disease risk variants, we further identified the cell-type disease genes and regulatory networks for schizophrenia and Alzheimer’s disease. The celltype regulatory elements (e.g., enhancers) in the networks were also found to be potential pleiotropic regulatory loci for a variety of diseases. Further enrichment analyses including gene ontology and KEGG pathways revealed potential novel cross-disease and disease-specific molecular functions, advancing knowledge on the interplays among genetic, transcriptional and epigenetic risks at the cellular resolution between neurodegenerative and neuropsychiatric diseases. Finally, we summarized our computational analyses as a general-purpose pipeline for predicting gene regulatory networks via multi-omics data.


2021 ◽  
Vol 12 ◽  
Author(s):  
Hae Deok Jung ◽  
Yoo Jin Sung ◽  
Hyun Uk Kim

Chemotherapy is a mainstream cancer treatment, but has a constant challenge of drug resistance, which consequently leads to poor prognosis in cancer treatment. For better understanding and effective treatment of drug-resistant cancer cells, omics approaches have been widely conducted in various forms. A notable use of omics data beyond routine data mining is to use them for computational modeling that allows generating useful predictions, such as drug responses and prognostic biomarkers. In particular, an increasing volume of omics data has facilitated the development of machine learning models. In this mini review, we highlight recent studies on the use of multi-omics data for studying drug-resistant cancer cells. We put a particular focus on studies that use computational models to characterize drug-resistant cancer cells, and to predict biomarkers and/or drug responses. Computational models covered in this mini review include network-based models, machine learning models and genome-scale metabolic models. We also provide perspectives on future research opportunities for combating drug-resistant cancer cells.


Sign in / Sign up

Export Citation Format

Share Document